Drug Trial Radar · NCT04370587
A Clinical Study of Intratumoral MVR-T3011 (T3011) Given as a Single Agent and in Combination With Intravenous Pembrolizumab in Participants With Advanced or Metastatic Solid Tumors
Last checked: Nov 19, 2026Latest source record: Oct 8, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
30
Planned (sponsor's estimate)
Start
Sep 17, 2020
Primary completion
Sep 22, 2026
Study completion Jan 10, 2027
Sponsor
- Lead sponsor
- ImmVira Pharma Co. LtdIndustry
- Sponsor type
- Industry
- First posted
- May 1, 2020
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a Phase 1/2a, open-label, study to evaluate the safety and preliminary efficacy of intratumoral T3011 given alone and in combination with intravenous pembrolizumab in partients with advanced or metastatic solid tumors.
Conditions
- Solid Tumor
- Melanoma
- HNSCC
- Sarcoma
- Squamous Cell Carcinoma
- NSCLC
Interventions
T3011Biological
T3011 will be administered up to 4mL as an intratumoral injection given Q2W.
T3011 + pembrolizumabCombination product
T3011 will be administered up to 4mL as an intratumoral injection in combination with intravenous pembrolizumab given Q3W.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Safety and tolerability of escalating doses T3011Time frame: Up to 2 years from first dose of T3011
- To determine the dose(s) of T3011 to be examined in Phase 2aTime frame: Through the first two T3011 injections (approximately 28 days)
- Safety and tolerability of T3011 dose(s) selected from Phase 1 in disease specific cohortsTime frame: Up to 2 years from first dose of T3011
- Characterize the safety and tolerability of T3011 in combination with pembrolizumabTime frame: Up to 2 years from first dose of T3011
- Characterize the safety and tolerability of T3011 in combination with pembrolizumab in participants who progress on T3011 aloneTime frame: Up to 2 years from first dose of T3011
Locations
9 sites in 2 countries. Site status is shown where the registry gives one.
Banner MD Anderson Cancer Center
Gilbert, Arizona · Completed
Massachusetts General Hospital
Boston, Massachusetts · Recruiting
Dana Farber Cancer Institute
Boston, Massachusetts · Recruiting
University of Pittsburgh Medical Center
Pittsburgh, Pennsylvania · Recruiting
Mary Crowley Cancer Research
Dallas, Texas · Recruiting
Virginia Cancer Specialists
Fairfax, Virginia · Recruiting
Southern Oncology
Bedford Park, Australia · Recruiting
Peninsula & South Eastern Haematology and Oncology Group
Frankston, Australia · Recruiting
The Alfred
Melbourne, Australia · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.